Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 41

1.

AKT kinase pathway: a leading target in cancer research.

Kumar A, Rajendran V, Sethumadhavan R, Purohit R.

ScientificWorldJournal. 2013 Nov 13;2013:756134. doi: 10.1155/2013/756134. Review.

PMID:
24327805
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells.

Vakana E, Arslan AD, Szilard A, Altman JK, Platanias LC.

PLoS One. 2013 Nov 18;8(11):e78780. doi: 10.1371/journal.pone.0078780. eCollection 2013.

PMID:
24260131
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor.

Airiau K, Mahon FX, Josselin M, Jeanneteau M, Belloc F.

Cell Death Dis. 2013 Oct 3;4:e827. doi: 10.1038/cddis.2013.309.

PMID:
24091670
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Signal transduction in the chronic leukemias: implications for targeted therapies.

Ahmed W, Van Etten RA.

Curr Hematol Malig Rep. 2013 Mar;8(1):71-80. doi: 10.1007/s11899-012-0150-1. Review.

PMID:
23307472
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells.

Kuwatsuka Y, Minami M, Minami Y, Sugimoto K, Hayakawa F, Miyata Y, Abe A, Goff DJ, Kiyoi H, Naoe T.

Blood Cancer J. 2011 May;1(5):e17. doi: 10.1038/bcj.2011.16. Epub 2011 May 13.

PMID:
22829152
[PubMed]
Free PMC Article
6.

Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer.

Baba Y, Fujii M, Tokumaru Y, Kato Y.

J Oncol. 2012;2012:986725. doi: 10.1155/2012/986725. Epub 2012 Mar 26.

PMID:
22545054
[PubMed]
Free PMC Article
7.

S6K1 determines the metabolic requirements for BCR-ABL survival.

Barger JF, Gallo CA, Tandon P, Liu H, Sullivan A, Grimes HL, Plas DR.

Oncogene. 2013 Jan 24;32(4):453-61. doi: 10.1038/onc.2012.70. Epub 2012 Mar 5.

PMID:
22391570
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.

Vakana E, Platanias LC.

Oncotarget. 2011 Dec;2(12):1322-8. Review.

PMID:
22249159
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-Duvaz I, Druker BJ, Springer C, Marais R.

Cancer Cell. 2011 Dec 13;20(6):715-27. doi: 10.1016/j.ccr.2011.11.004.

PMID:
22169110
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD.

Yang X, Liu S, Kharbanda S, Stone RM.

Leuk Res. 2012 Feb;36(2):205-11. doi: 10.1016/j.leukres.2011.09.006. Epub 2011 Dec 3.

PMID:
22142798
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.

Vakana E, Altman JK, Glaser H, Donato NJ, Platanias LC.

Blood. 2011 Dec 8;118(24):6399-402. doi: 10.1182/blood-2011-01-332783. Epub 2011 Oct 21.

PMID:
22021366
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma.

Cloninger C, Bernath A, Bashir T, Holmes B, Artinian N, Ruegg T, Anderson L, Masri J, Lichtenstein A, Gera J.

Mol Cancer Ther. 2011 Dec;10(12):2244-56. doi: 10.1158/1535-7163.MCT-11-0478. Epub 2011 Sep 12.

PMID:
21911485
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.

Joha S, Nugues AL, H├ętuin D, Berthon C, Dezitter X, Dauphin V, Mahon FX, Roche-Lestienne C, Preudhomme C, Quesnel B, Idziorek T.

Oncogene. 2012 Mar 15;31(11):1419-30. doi: 10.1038/onc.2011.328. Epub 2011 Aug 1.

PMID:
21804606
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.

Sheng Z, Ma L, Sun JE, Zhu LJ, Green MR.

Blood. 2011 Sep 8;118(10):2840-8. doi: 10.1182/blood-2010-12-322537. Epub 2011 Jun 29.

PMID:
21715304
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.

Chen W, Drakos E, Grammatikakis I, Schlette EJ, Li J, Leventaki V, Staikou-Drakopoulou E, Patsouris E, Panayiotidis P, Medeiros LJ, Rassidakis GZ.

Mol Cancer. 2010 Nov 10;9:292. doi: 10.1186/1476-4598-9-292.

PMID:
21067588
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling.

Sathaliyawala T, O'Gorman WE, Greter M, Bogunovic M, Konjufca V, Hou ZE, Nolan GP, Miller MJ, Merad M, Reizis B.

Immunity. 2010 Oct 29;33(4):597-606. doi: 10.1016/j.immuni.2010.09.012. Epub 2010 Oct 7.

PMID:
20933441
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis.

Klusmann JH, Godinho FJ, Heitmann K, Maroz A, Koch ML, Reinhardt D, Orkin SH, Li Z.

Genes Dev. 2010 Aug 1;24(15):1659-72. doi: 10.1101/gad.1903410.

PMID:
20679399
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.

Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, Druker BJ, Donato NJ, Altman JK, Barr S, Platanias LC.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12469-74. doi: 10.1073/pnas.1005114107. Epub 2010 Jun 28.

PMID:
20616057
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.

Ahmad R, Liu S, Weisberg E, Nelson E, Galinsky I, Meyer C, Kufe D, Kharbanda S, Stone R.

Mol Cancer Res. 2010 Jul;8(7):986-93. doi: 10.1158/1541-7786.MCR-10-0154. Epub 2010 Jun 22.

PMID:
20571062
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin.

Li G, Miskimen KL, Wang Z, Xie XY, Tse W, Gouilleux F, Moriggl R, Bunting KD.

Leukemia. 2010 Aug;24(8):1397-405. doi: 10.1038/leu.2010.131. Epub 2010 Jun 10.

PMID:
20535152
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk